OPKO Health, Inc. Foreign Currency Transaction Gain (Loss), before Tax
OPKO Health, Inc. (OPK) reported Foreign Currency Transaction Gain (Loss), before Tax of $100.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-08-28
- OPKO Health, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was $100.00K, a 96.15% decline year-over-year.
- OPKO Health, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was $1.50M, a 1400.00% increase year-over-year.
- OPKO Health, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was -$500.00K.
- OPKO Health, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was $1.10M, a 73.17% decline year-over-year.
- OPKO Health, Inc. foreign currency transaction gain (loss), before tax for fiscal 2025 was -$2.00M.
- OPKO Health, Inc. foreign currency transaction gain (loss), before tax for fiscal 2024 was -$3.80M, a 416.67% decline from fiscal 2023.
- OPKO Health, Inc. foreign currency transaction gain (loss), before tax for fiscal 2023 was $1.20M.
- OPKO Health, Inc. foreign currency transaction gain (loss), before tax for fiscal 2022 was -$1.80M.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 3 month as first filed | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month as first filed | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month as first filed | Foreign Currency Transaction Gain (Loss), before Tax 12 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $100.00K 10-Q/A · filed 2026-08-28 | $1.40M 10-Q/A · filed 2026-08-28 | $1.10M derived: sum of 3 quarters · filed 2026-08-28 | $2.20M derived: sum of 4 quarters · filed 2026-08-28 | ||||
| 2026-03-31 | $1.50M 10-Q/A · filed 2026-08-28 | $1.00M derived: sum of 2 quarters · filed 2026-08-28 | $2.10M derived: sum of 3 quarters · filed 2026-08-28 | $4.70M derived: sum of 4 quarters · filed 2026-08-28 | ||||
| 2025-12-31 | -$500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $600.00K derived: sum of 2 quarters · filed 2026-02-26 | $3.20M derived: sum of 3 quarters · filed 2026-08-28 | -$2.00M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $1.10M 10-Q · filed 2025-10-29 | $3.70M derived: sum of 2 quarters · filed 2026-08-28 | -$1.50M 10-Q · filed 2025-10-29 | -$100.00K derived: sum of 4 quarters · filed 2026-08-28 | ||||
| 2025-06-30 | $2.60M 10-Q/A · filed 2026-08-28 | -$2.60M 10-Q · filed 2025-07-31 | $2.50M 10-Q/A · filed 2026-08-28 | -$2.50M 10-Q · filed 2025-07-31 | -$1.20M derived: sum of 3 quarters · filed 2026-08-28 | $2.90M derived: sum of 4 quarters · filed 2026-08-28 | ||
| 2025-03-31 | $100.00K 10-Q/A · filed 2026-08-28 | -$3.80M derived: sum of 2 quarters · filed 2026-08-28 | $300.00K derived: sum of 3 quarters · filed 2026-08-28 | -$1.00M derived: sum of 4 quarters · filed 2026-08-28 | ||||
| 2024-12-31 | -$3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $200.00K derived: sum of 2 quarters · filed 2026-02-26 | -$1.10M derived: sum of 3 quarters · filed 2026-02-26 | -$3.80M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $4.10M 10-Q · filed 2025-10-29 | $2.80M derived: sum of 2 quarters · filed 2025-10-29 | $100.00K 10-Q · filed 2025-10-29 | $8.60M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | -$1.30M 10-Q · filed 2025-07-31 | -$4.00M 10-Q · filed 2025-07-31 | $4.50M derived: sum of 3 quarters · filed 2026-02-26 | $700.00K derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $2.70M 10-Q · filed 2025-05-01 | -$2.70M 10-Q · filed 2024-05-07 | $5.80M derived: sum of 2 quarters · filed 2026-02-26 | $2.00M derived: sum of 3 quarters · filed 2026-02-26 | $2.90M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$700.00K derived: sum of 2 quarters · filed 2026-02-26 | $200.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.20M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | -$3.80M 10-Q · filed 2024-11-07 | $3.80M 10-Q · filed 2023-11-06 | -$2.90M derived: sum of 2 quarters · filed 2024-11-07 | -$1.90M 10-Q · filed 2024-11-07 | $1.90M 10-Q · filed 2023-11-06 | -$11.30M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-06-30 | $900.00K 10-Q · filed 2024-08-07 | $2.00M 10-Q · filed 2024-08-07 | -$7.50M derived: sum of 3 quarters · filed 2025-03-03 | -$1.70M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-03-31 | $1.00M 10-Q · filed 2024-05-07 | -$8.40M derived: sum of 2 quarters · filed 2025-03-03 | -$2.60M derived: sum of 3 quarters · filed 2025-03-03 | -$1.80M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | -$9.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$3.60M derived: sum of 2 quarters · filed 2025-03-03 | -$2.80M derived: sum of 3 quarters · filed 2025-03-03 | -$1.80M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | $5.80M 10-Q · filed 2023-11-06 | -$5.80M 10-Q · filed 2022-11-08 | $6.60M derived: sum of 2 quarters · filed 2023-11-06 | $7.60M 10-Q · filed 2023-11-06 | -$7.60M 10-Q · filed 2022-11-08 | $11.90M derived: sum of 4 quarters · filed 2024-03-01 | ||
| 2022-06-30 | $800.00K 10-Q · filed 2023-08-03 | $1.80M 10-Q · filed 2023-08-03 | $6.10M derived: sum of 3 quarters · filed 2024-03-01 | $5.00M derived: sum of 4 quarters · filed 2024-03-01 | ||||
| 2022-03-31 | $1.10M 10-Q · filed 2023-05-03 | $5.30M derived: sum of 2 quarters · filed 2024-03-01 | $4.20M derived: sum of 3 quarters · filed 2024-03-01 | $3.80M derived: sum of 4 quarters · filed 2024-03-01 | ||||
| 2021-12-31 | $4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $3.10M derived: sum of 2 quarters · filed 2024-03-01 | $2.70M derived: sum of 3 quarters · filed 2024-03-01 | -$1.40M 10-K · filed 2024-03-01 | ||||
| 2021-09-30 | -$1.10M 10-Q · filed 2022-11-08 | -$1.50M derived: sum of 2 quarters · filed 2022-11-08 | -$5.60M 10-Q · filed 2022-11-08 | |||||
| 2021-06-30 | -$400.00K 10-Q · filed 2022-08-04 | $4.40M 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | $4.80M 10-Q · filed 2022-05-09 | |||||||
| 2020-12-31 | $1.60M 10-K · filed 2023-02-27 | |||||||
| 2019-12-31 | $400.00K 10-K · filed 2022-03-01 | |||||||
| 2018-12-31 | $1.90M 10-K · filed 2021-02-18 | |||||||
| 2017-12-31 | $1.40M 10-K · filed 2020-03-02 | |||||||
| 2016-12-31 | $800.00K 10-K · filed 2019-03-01 | |||||||
| 2015-12-31 | -$1.62M derived: 8-K 12 month − 10-Q 9 month · filed 2019-01-29 | -$2.10M derived: sum of 2 quarters · filed 2019-01-29 | -$1.93M derived: sum of 3 quarters · filed 2019-01-29 | -$2.40M 8-K · filed 2019-01-29 | ||||
| 2015-09-30 | -$476.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$303.00K derived: sum of 2 quarters · filed 2015-11-09 | -$776.00K 10-Q · filed 2015-11-09 | -$4.57M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2015-06-30 | $173.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | -$300.00K 10-Q · filed 2015-08-05 | -$4.09M derived: sum of 3 quarters · filed 2017-03-01 | -$5.92M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2015-03-31 | -$473.00K 10-Q · filed 2015-05-11 | -$4.26M derived: sum of 2 quarters · filed 2017-03-01 | -$6.10M derived: sum of 3 quarters · filed 2017-03-01 | -$6.25M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2014-12-31 | -$3.79M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$5.62M derived: sum of 2 quarters · filed 2017-03-01 | -$5.78M derived: sum of 3 quarters · filed 2017-03-01 | -$4.80M 10-K · filed 2017-03-01 | -$945.00K 10-K · filed 2015-02-27 | |||
| 2014-09-30 | -$1.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$1.98M derived: sum of 2 quarters · filed 2015-11-09 | -$1.01M 10-Q · filed 2015-11-09 | -$2.72M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | -$152.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $824.00K 10-Q · filed 2015-08-05 | -$885.00K derived: sum of 3 quarters · filed 2016-02-29 | $974.00K derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $976.00K 10-Q · filed 2015-05-11 | -$733.00K derived: sum of 2 quarters · filed 2016-02-29 | $1.13M derived: sum of 3 quarters · filed 2016-02-29 | $336.00K derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | -$1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $150.00K derived: sum of 2 quarters · filed 2016-02-29 | -$640.00K derived: sum of 3 quarters · filed 2016-02-29 | -$300.00K 10-K · filed 2016-02-29 | $2.39M 10-K · filed 2014-03-03 | |||
| 2013-09-30 | $1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $1.07M derived: sum of 2 quarters · filed 2014-11-07 | $1.41M 10-Q · filed 2014-11-07 | $1.12M derived: sum of 4 quarters · filed 2015-02-27 | ||||
| 2013-06-30 | -$790.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$450.00K 10-Q · filed 2014-08-11 | -$740.00K derived: sum of 3 quarters · filed 2015-02-27 | |||||
| 2013-03-31 | $340.00K 10-Q · filed 2014-05-09 | $50.00K derived: sum of 2 quarters · filed 2015-02-27 | ||||||
| 2012-12-31 | -$290.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | -$86.00K 10-K · filed 2015-02-27 | ||||||
| 2012-09-30 | $204.00K 10-Q · filed 2013-11-12 | |||||||
| 2011-12-31 | -$363.00K 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |